Pfizer beats quarterly estimates regardless of Covid product decline, reaffirms modest outlook – Company Technique & Outlook

Pfizer on Tuesday reported fourth-quarter outcomes that topped estimates even amid dwindling demand for its Covid merchandise, whereas reaffirming its modest 2026 steerage that rattled buyers in December.

The pharmaceutical big is seeking to longer-term investments in its pipeline, together with its $10 billion acquisition of the weight problems biotech Metsera, to counter waning Covid product gross sales and declines from older medication. Pfizer moved to indicate the promise of that funding Tuesday, when it additionally reported mid-stage knowledge exhibiting that an weight problems injection from Metsera may be taken as soon as a month and drive stable weight reduction.

As well as, Pfizer is on observe to chop prices by about $7.7 billion by the top of 2027 as a part of two separate initiatives.

This is what the corporate reported for the fourth quarter in contrast with what Wall Avenue was anticipating, based mostly on a survey of analysts by LSEG: 

• Earnings per share: 66 cents adjusted vs. 57 cents anticipated
• Income: $17.56 billion vs. $16.95 billion anticipated

Pfizer shares fell greater than 3% on Tuesday.

Pfizer reported income of $17.56 billion for the fourth quarter, down round 1% from the identical interval a 12 months in the past. That’s largely due to decrease demand for its Covid vaccine and Paxlovid, an antiviral tablet for the virus.

The corporate booked a internet lack of $1.65 billion, or 29 cents per share. That compares with internet revenue of $410 million, or 7 cents per share, throughout the identical interval a 12 months in the past.

Excluding sure gadgets, together with restructuring expenses and prices related to intangible property, the corporate posted earnings per share of 66 cents for the quarter.

Pfizer expects 2026 adjusted revenue to come back in between $2.80 and $3 per share, and income to whole $59.5 billion to $62.5 billion. These gross sales would largely be flat in contrast with 2025 income.

Pfizer beforehand mentioned the lackluster income outlook is available in half from declining gross sales of its Covid vaccine and antiviral tablet Paxlovid, which it expects to fall by about $1.5 billion 12 months over 12 months to $5 billion. 

The corporate additionally pointed to a different roughly $1.5 billion year-over-year anticipated drop in gross sales attributable to sure merchandise dropping their market exclusivity. Some blockbuster medication, corresponding to the corporate’s pneumonia vaccine Prevnar, are going through extra competitors from rivals.

In December, Pfizer CFO Dave Denton advised buyers there may be additionally “value compression and margin compression baked into” the corporate’s 2026 steerage because it plans to supply “deeper reductions” in its Medicaid enterprise as a part of a landmark drug pricing deal struck with President Donald Trump. 

Underneath that settlement, Pfizer agreed to promote its present medication to Medicaid sufferers on the lowest value supplied in different developed nations and assure the identical “most-favored-nation” pricing on its new medication for Medicare, Medicaid and business payers. In return, the corporate will get a three-year exemption from tariffs. 

Pfizer’s Xeljanz and Xeljanz XR, remedies for rheumatoid arthritis and different inflammatory circumstances, had been chosen in January for the third spherical of Medicare drug value negotiations. New negotiated costs will come into impact in 2028.